PPT-Practical Considerations for Symptom Relief with Medical Cannabis

Kelly Butterman Lead Cannabis Educator Verdes Cannabis kbuttermanverdesfoundationorg Objectives Drug Scheduling Clinicians are limited to the type of guidance they can provide to patients because of the way cannabis is scheduled as a drug. Dr. Bareket Schiff Keren. Some history. GLOBAL. AND. LOCAL. Gan. -. zi. -gun-nu. – the drug that takes away the mind. Azallu. . – hand of ghost, poison of all limbs. (neurological diseases?). U.S. Federal Patent. http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6630507.PN.&OS=PN/6630507&RS=PN/6630507. Talking to your doctor, Safety and Update on Clinical Trials. Lubov. . Romantseva. , MD. Child Neurology and Epilepsy. Rush University Medical Center. Nov 12, 2016. Disclosures. I have no financial interest in any pharmaceutical company mentioned in this presentation. 11/. . 12. . /. . 16. Bob Morgan. Illinois Medical Cannabis Pilot Program Act. 2. Four . year pilot program beginning January 1, 2014 entitled the . “Illinois Compassionate Use of Medical . Cannabis Pilot Program . September 2016. Implementation Timeline. Office of Compassionate Use Established. : July 1, 2014. Florida Administrative Code Chapter 64-4 Promulgated, Final Rule Upheld: . May 28, 2015. Dispensing Organization Applications Accepted: . Presentation to. University of Maryland Medical School. Quarterly Meeting. October 8, 2015. by. Deborah . Miran. Commissioner. Maryland Medical Cannabis Commission. Medical Cannabis – An Update. Milestones of the Twentieth Century . Gregg VandeKieft, MD, MA. WSHPCO “Expanding dimensions in hospice & palliative care”. Chelan, . wa. October 10, 2017. Disclosure. Dr. VandeKieft does not have any conflicts of interest to disclose. He will discuss medical applications of cannabis, but will not discuss off-label use of medications.. Learning Objectives . Review the New Mexico Cannabis Program.. Describe how cannabis works in the body.. Identify available dosage forms and their benefits and cautions. . Identify common adverse effects of medical cannabis use.. PDI Medical. What is Neuropathy?. Acquired Neuropathy Causes. Symptoms/Subtypes. Mainstream Treatments. Pain Relievers. OTC medications. Opioids. Anti-seizure medications. gabapentin (. Neurotin. ). pregabalin (Lyrica). Qualifying medical conditions are typically defined on a state level and are required to permit the order of medical cannabis.. Objectives: . To identify and map the most recently (2016-2019) published clinical and scientific literature across approved conditions for medical cannabis, and; . 2021 ANNUAL REPORT. Myles J. Willingham. Division Chief of Medical Cannabis Patient Program. Table of Contents. . Objectives. Explain the history of CBD and Hemp. Discuss cannabis-based approved medications in the US. Explore the marketing and efficacy of CBD. Discuss the legality of the use of CBD in the nation. www.hivguidelines.org. JANUARY 2022. NYSDOH AIDS Institute Clinical Guidelines Program. Purpose of This Guideline. Provide clinicians with a framework for implementing the therapeutic use of medical cannabis in their outpatient settings in NYS.. Prohibition. Common Questions. Violations and Sanctions. Legalization . History. Cannabinoids have been on the WADA Prohibited List since 2004. Prohibited List inclusion criteria:. The substance must meet two of the following:.